Clinical trial
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
NCT00421122 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00421122 |
|---|---|
| Title | Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD |
| Official title | A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Intervention type | Drug |
| Interventions | budesonide/formoterol (Symbicort), budesonide (Pulmicort), terbutaline sulfate (Bricasol) |
| Enrollment | 315 |
| Start date | Sep 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Jan 11, 2007 |
| Last update posted | Mar 27, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: